Shenzhen TargetRx

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
ALK;ROS1Small molecule
Non-Small Cell Lung Cancer
Phase 1/2
BCL-2Small molecule
Acute Myeloid Leukemia
Phase 1
Undisclosed / early pipelineSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.